Explore every episode of the podcast pharmaphorum Podcast

The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpointing and showcasing repeatable use cases to shape the targeted use of next-generation artificial intelligence and machine learning (AI-ML) innovation, particularly in the form of GenAI.

In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Manny Belabe, senior VP of customer success at ArisGlobal, about the Council and the role it seeks to play in furthering the success of GenAI in life sciences R&D.

Discussing also ArisGlobal’s LifeSphere NavaX GenAI features and functionality, Belabe notes too that a platform-centric development approach, based on common modules, can be leveraged to reduce data redundancy and general maintenance of that data.

At the present moment, however, there is also the pressing concern of sustainability in all sectors, and Belabe addresses practical issues around cooling infrastructure and space requirements for these technologies, as well.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Fiske, chief scientific officer of Mythic Therapeutics, about minimising side effects for patients and the notion of patient-centred science.

We've recently passed the midpoint of 2024, so it's a good time to check in on trends – in this case, trends in the clinical trial space.

In today's podcast, brought to you by Advanced Clinical, host Jonah Comstock is joined by Jason Casarella, EVP of business development and marketing at Advanced Clinical and Caroline Redecker, chief strategy officer at Advanced Clinical, to discuss some of the findings in their recently released clinical trends report.

One of the biggest trends in the report is the rise of clinical trial site networks, and Casarella and Redecker drill down on why that’s happening and what it means for investigators. They also discuss how patient recruitment is changing in light of both changing technology and infrastructures, and new expectations about representation and diversity.

The conversation also veers into biotech investment trends and how those impact clinical trials, as well as the rise of AI and the various use cases being found for it in clinical research. Tune in for a wide-ranging snapshot into the evolving world of clinical research.

Editor in Chief Jonah Comstock welcomes back returning guest Dr. Jennifer Jones-McMeans, divisional vice president for global affairs for Abbot’s vascular business. Jennifer was on the podcast just over a year ago to talk about the importance of clinical trial diversity, and she’s back with an update on that important topic, as well as some news from Abbott in that area.

In this episode of the pharmaphorum podcast, brought to you by Advanced Clinical, Advanced Clinical’s SVP Strategic Resourcing Steve Mattas and VP of Global Talent and Client Delivery James Nyssen speak with host Jonah Comstock about findings from a recent report by their company on the current personnel dynamics in pharma.

As DTx Europe came to a close at the British Medical Association in London, pharmaphorum web editor Nicole Raleigh spoke with Digital Medicine Society (DiMe) program lead, Alex Despotovic, discussing adoption of digital therapeutics and digital technologies in general in clinical practice, and the impact of the event itself overall.

Recently attending the Veeva R&D and Quality Summit in Madrid, pharmaphorum web editor Nicole Raleigh sat down with Veeva’s president of Europe, Chris Moore. The event seen as a chance to bring the whole industry together, Moore explained how there is an excitement in the industry currently, with more drugs being developed, more conditions being treated – including those not before addressed – and that Veeva is endeavouring to do what it can to help raise the industry capabilities. So it is that the event has become a test bed to see whether the company is on the right track.

In the latest instalment of the pharmaphorum podcast, Editor in Chief Jonah Comstock is joined by Dr Noura Abul-Husn, VP of genomic health at 23andMe. 

This week, pharmaphorum editor-in-chief Jonah Comstock headed to not one but two back-to-back events in the US. Starting with the American Society of Clinical Oncology’s (ASCO) annual conference in Chicago, before hitting the floor at the BIO International Convention in Boston, there was plenty of innovation, news, and expert knowledge on display.

Fresh from the floor of BIO International, Jonah sat down with pharmaphorum Deep Dive editor Eloise McLennan to reflect on the biggest topics and trends from each event – and the impact these developments may have on pharma over the coming months.

On the final day of Reuters Pharma Barcelona back in March, web editor Nicole Raleigh sat down with Graphite Digital’s CEO, Rob Verheul. The company – which has been working in the industry for 13 years now – has most recently been focusing on HCP engagement at a global scale, through use of digital channels.

In this episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock catches up with Adityo Prakash, CEO of Verseon, to shed some light on what the potential of AI in drug discovery really is.

Back in March at Reuters Pharma Barcelona, pharmaphorum’s web editor Nicole Raleigh met up with CEO of Within3, Lance Hill. Having met up in Nice in 2022, it was interesting to ‘get up to speed’ a year later.

Discussing how the industry is ‘starved’ of insights – with so much data from so many sources, fragmented, regional, and disconnected, that decisions cannot be reached in the timeframes necessary – Hill defines insights as the epiphany moments; what permit the right actions and determine the trajectory of a therapy.

 In the latest instalment of the pharmaphorum podcast, Editor in Chief Jonah Comstock connects with Kylie O’Keefe to talk about gene therapy in rare diseases. 

They discuss what different gene therapies have in common and how some particular therapies work. They also talk about what gene therapy means for the industry and for patients, in particularly the paradigm shift of disease-modifying therapies. 

In this latest pharmaphorum podcast, web editor Nicole Raleigh speaks with Michael Kyle, chief medical officer at Currax Pharmaceuticals – a company working to advance a greater understanding of how to effectively treat obesity – about perceptions and options beyond the bounds of GLP-1s, including evolution of hypertension treatments.

On 21st June, London’s prestigious Royal Society of Medicine will play host to some of the sharpest minds in healthcare as they come together for the inaugural World Without Disease conference, developed by pharmaphorum and the CWWDA.

One of these minds is Daniel Zakowski, CEO of Ready, Set, Food!, who will be taking the stage to discuss why preventing childhood food allergies is an important step in the journey towards the vision of a disease-free world.

Having any chronic health condition is complicated, difficult, and scary. But add in a cultural or social stigma and you create whole new levels of challenge. 

In today’s pharmaphorum podcast, brought to you by Cerner Enviza, an Oracle company, editor in chief Jonah Comstock welcomes Nate Way, senior evidence generation lead at Cerner Enviza and James Geary MBA, MHA, a data analyst who also lives with Cerebral Palsy and anxiety and depression.  

In this latest mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Tommy Bramley, SVP of global consulting at Amerisource Bergen, whilst attending Reuters Pharma Barcelona.

On today’s pharmaphorum podcast, Evidation’s Executive Chair of the Board Deborah Kilpatrick joins host Jonah Comstock to talk about healthcare data collection in 2023 and how it intersects with stakeholders across the ecosystem, from tech and pharma companies to research participants. 

In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Simon Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialise long-standing research programmes from Gustav Roussy, Institut Curie, the University of Strasbourg, and Pierre Fabre, to develop drugs that overcome tumour resistance to existing drug treatments.

In today’s pharmaphorum podcast, brought to you by Lannett Corporation, editor in chief Jonah Comstock first chats with Timothy Crew, CEO of Lannett. Crew talks about the contract development manufacturing organisation (CDMO) business and why local manufacturing is important in the United States.

Then, in part 2, Jonah talks to Tom Lewis, Lannett’s VP of Global Supply Chain and CDMO Management. They discuss Lannett’s CDMO business more broadly, how it works, and why it’s an important offering in today’s pharma landscape.

Almost everyone seems to agree that drug prices are too high. But that agreement stops when it comes to the question of why they’re so high, and to the question of how to bring them down. 

Goodroot CEO Mike Waterbury and Nuwae Health CEO Ralph Pisano discuss how the community of Goodroot companies, including Nuwae, are attacking that issue from different angles. 

Angelini Ventures is a recently launched investment fund seeking companies that are transformational in healthcare. Founder of pharmaphorum and Healthware Group's chief content officer, Paul Tunnah, talks with Nils Bottler, who recently joined Angelini Ventures as Principal, about his career and where Angelini Ventures aims to have an impact.

For the newest pharmaphorum podcast, editor in chief Jonah Comstock welcomes Dr. Kristina Allikmets, SVP and head of R&D at Takeda’s plasma-derived therapies business unit. 

In this episode of the pharmaphorum podcast, host Jonah Comstock welcomes Marc de Garidel, CEO of CinCor Pharma, which was just recently sold to AstraZeneca for more than $1 billion USD. Marc tells Jonah all about CinCor and its unique approach to hypertension, how the AstraZeneca deal came about, and what happens next.

The field of muscle stem cell research has been tangibly developing over the decades and in today’s pharmaphorum podcast wed editor Nicole Raleigh speaks with Dr Michael Rudnicki, co-founder and CSO of Satellos Biosciences, a company dedicated to developing novel therapeutics based on this science for those who live with Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases.

No matter what industry you’re in, artificial intelligence is a major topic around the water cooler. But while AI in popular culture may be at a peak of hype, AI in pharma is strending toward a moment of maturity, reliability, and scalability.

In today’s pharmaphorum podcast, brought to you by Syneos Health, Leigh Householder, EVP and MD technology and data solutions at Syneos Health and Noolie Gregory, VP decentralised clinical trial operations at Syneos Health, join host Jonah Comstock to talk about the Syneos Health 2023 Health Trends Report, particularly the opening section on AI: Finally Fit for Purpose.

At the beginning of February, pharmaphorum web editor Nicole Raleigh travelled to Rome to cover the inaugural VITA Accelerator demo day. After the event, VITA’s senior programme manager Anastasiya Markvarde and managing director Paolo Borella took time to discuss the ethos behind the accelerator and the future of digital health start-ups in Italy and beyond.

Angelini Ventures is a recently launched investment fund seeking companies that are transformational in healthcare. pharmaphorum founder and Healthware Chief Content Officer Paul Tunnah, talks with co-Managing Director Elia Stupka about the new €300 million fund, how it started, how it’s going, and what health innovation looks like from the investor’s perspective.

This podcast was produced in partnership with Angelini Ventures and was originally published on Matthew Holt’s Healthcare Blog Podcast.

 This time around on the pharmaphorum podcast, Editor in Chief Jonah Comstock chats with Nathan Buchbinder, cofounder and chief product officer at Proscia about pathology data, why it has taken so long to digitise it, and what the possibilities are when this data is freed from its historical siloes. 

In the newest episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna. 

pharmaphorum Editor-in-Chief Jonah Comstock and pharmaphorum Founder Paul Tunnah headed to San Francisco this week for the JP Morgan conference, the annual elbow-rubbing opportunity for biotech bigwigs. This is the first time the show has been back in person since COVID, and, despite some less than ideal weather, attendees were excited to resume in person collaboration.

During The Economist’s 8th Annual World Cancer Series congress in Brussels last month, web editor Nicole Raleigh sat down to discuss the event and its themes with Greg Rossi, senior vice president, head of oncology Europe and Canada at AstraZeneca .

Speaking with Rob Verheul, CEO of Graphite Digital, at Anthropy 2022 at the Eden Project, pharmaphorum web editor Nicole Raleigh enjoyed a minute discussing the event and what specifically had attracted Verheul to attend.

As we close out the year, the pharmaphorum editorial team sits down together for a roundtable discussion of some of the biggest trends they’ve tracked this year in the world of pharma. 

While at Anthropy 2022, pharmaphorum’s web editor Nicole Raleigh briefly spoke with Karyn Johnston, chief executive of East Cheshire Hospice, who had taken part in the Adelphi Group’s panel, ‘Later life care and dementia’.

In today’s pharmaphorum podcast, Orr Inbar, co-founder and CEO of QuantHealth, a Tel Aviv-based AI-powered clinical trial design company, discusses how advances in data and AI can help.

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure that is the Chiesi Group’s new €85 million Biotech Centre of Excellence, pharmaphorum web editor Nicole Raleigh spoke with Chiesi’s head of global manufacturing, Antonio Magnelli.

On today’s pharmaphorum podcast, host Jonah Comstock takes us to the PharmStars presentation last month at the Boston Seaport, with interviews conducted at the event. The topic: Innovations in Real-World Evidence. 

Flying into London recently for the Jefferies Conference, Novavax’s EVP, chief commercial officer, and chief business officer John Trizzino, together with the company’s chief medical officer Filip Dubovsky, took time out of very packed schedules indeed to speak with pharmaphorum Web editor Nicole Raleigh in a small (though not always necessarily quiet) corner of the One Aldwych Hotel on the Strand.

In the newest episode of the pharmaphorum podcast, editor in chief Jonah Comstock chats with Gita Barry, EVP and GM of Immersive Healthcare at Penumbra, a therapeutic VR company.

Anthropy 2022 brought climate change to industry in Cornwall in (a very wet and windy) early November, settling cosily into the truly eco-minded environs of the Eden Project and firing up fervent and necessary conversations on sustainability, accessibility, and action plans.

Amidst all this, Adelphi Group’s CEO Stuart Cooper found a moment to sit with pharmaphorum web editor Nicole Raleigh and discuss just how exciting it was to bring to vibrant and discursive life the ethos of Anthropy – a united vision for British business, including pharma, and the future of this nation overall.

pharmaphorum Editor-in-Chief Jonah Comstock traveled to Las Vegas last week with thousands of other healthcare stakeholders for the HLTH 2022 conference.

In this post-show edition of the pharmaphorum podcast, Jonah welcomes Matthew Holt, editor of The Healthcare Blog and former digital health event organiser, to discuss the show itself and the content therein.

In this mini episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Sylvana Sinha, founder, chair, and CEO of Praava Health, Bangladesh’s fastest growing healthcare brand.

In this episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock chats with Howard Rose, head of health and wellness at Spatial about immersive audio: what it is, how it works, and how it can help in healthcare.

In the latest installment of the pharmaphorum podcast, Editor in Chief Jonah Comstock sits down with Russell Potterfield, CEO at Endevica Pharma.

A biotech CEO who comes from the business and investment worlds, Russell now runs Endevica, which is working on a novel therapy for cachexia, a wasting syndrome that accompanies many cancers.

In this episode of the pharmaphorum podcast, host Jonah Comstock taps XIL Health’s Susan Lang to better understand why big tech’s ventures into healthcare seem to stumble more often than not.

In a new episode of the pharmaphorum podcast - recorded back in March, during Women’s History Month - web editor Nicole Raleigh spoke with Johan van Hylckama Vlieg, co-founder and chief scientific officer of Freya Biosciences, a Series A-financed, clinical stage, microbial immunotherapy company in women’s health, discussing the role of the vaginal microbiome in fertility, before he was due to speak at the first-of-its-kind Microbes in Women’s Health Congress in Copenhagen.

In this special, live edition of the pharmaphorum podcast, recorded at the conclusion of Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock and pharmaphorum Web Editor Nicole Raleigh are joined by author, consultant, and podcast host Tony Estrella and Healthware Labs Managing Director Kristin Milburn to discuss their key takeaways from the show last week in Milan.

In mid-October, our Web Editor Nicole Raleigh and Deep Dive Editor Eloise McLellan traveled to Nice for the Reuters Pharma event.

This special episode includes a conversation recorded on-site with Nicole, Eloise, Virtual Science AI CEO Thomas Hughes, and VSAI VP of global patient affairs Geraldine Reilly.

And stay tuned for the second half of the episode, where Nicole speaks with Sabine Hutchison, CEO and co-founder of Seuss+, about the Dutch consulting firm’s work with smaller life science companies.

In this episode of the pharmaphorum, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health.